High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody

(MedPage Today) -- HOUSTON -- More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a pivotal trial. Overall...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news